Peregrine Pharmaceuticals Inc

Find Ratings Reports
PPHM : NASDAQ : Health Care
$0.36 -0.01 | -2.10%
Today's Range: 0.36 - 0.37
Avg. Daily Volume: 1,471,000
08/25/16 - 3:59 PM ET

Financial Analysis


PEREGRINE PHARMACEUTICLS INC's gross profit margin for the fourth quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. PEREGRINE PHARMACEUTICLS INC has average liquidity. Currently, the Quick Ratio is 1.12 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.

During the same period, stockholders' equity ("net worth") has decreased by 15.17% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q4 FY15 Q4 FY14
Net Sales ($mil)18.789.31
EBITDA ($mil)-11.3-11.93
EBIT ($mil)-11.92-12.17
Net Income ($mil)-11.88-12.14


Balance Sheet Q4 FY15 Q4 FY14
Cash & Equiv. ($mil)61.4168.0
Total Assets ($mil)109.0497.46
Total Debt ($mil)0.00.0
Equity ($mil)50.0759.04


Profitability Q4 FY15 Q4 FY14
Gross Profit Margin51.5151.44
EBITDA Margin-60.16-128.18
Operating Margin-63.44-130.74
Sales Turnover0.410.27
Return on Assets-51.03-51.66
Return on Equity-120.09-91.56
Debt Q4 FY15 Q4 FY14
Current Ratio1.422.16
Debt/Capital0.00.0
Interest Expense0.00.0
Interest Coverage0.00.0


Share Data Q4 FY15 Q4 FY14
Shares outstanding (mil)236.93193.35
Div / share0.00.0
EPS-0.05-0.07
Book value / share0.210.31
Institutional Own % n/a n/a
Avg Daily Volume1463931.01732282.0

Valuation


SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 1.75 indicates a discount versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 10.44. The price-to-sales ratio is similar to the S&P 500 average, but it is significantly below the industry average, indicating a discount. After reviewing these and other key valuation criteria, PEREGRINE PHARMACEUTICLS INC proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
PPHM NM Peers 43.43   PPHM NM Peers 21.06

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

PPHM's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

PPHM's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
PPHM NM Peers 29.93   PPHM NA Peers 0.49

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

PPHM's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
PPHM 1.75 Peers 10.44   PPHM 6.67 Peers 0.31

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

PPHM is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

PPHM is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
PPHM 1.96 Peers 555.79   PPHM 66.85 Peers 52.64

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

PPHM is trading at a significant discount to its industry on this measurement.

 

Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

PPHM has a sales growth rate that significantly exceeds its peers.

 

 

Latest Stock Upgrades/Downgrades